Celgene Co. (CELG) Director Sells $887,907.50 in Stock

Celgene Co. (NASDAQ:CELG) Director Gilla Kaplan sold 9,250 shares of the business’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the sale, the director now directly owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The sale was disclosed in a legal filing with the SEC, which is accessible through this link.

Gilla Kaplan also recently made the following trade(s):

  • On Tuesday, February 20th, Gilla Kaplan sold 9,250 shares of Celgene stock. The stock was sold at an average price of $94.83, for a total transaction of $877,177.50.

Celgene Co. (CELG) opened at $93.89 on Thursday. The company has a current ratio of 4.99, a quick ratio of 4.80 and a debt-to-equity ratio of 2.29. The firm has a market cap of $70,591.68, a PE ratio of 13.68, a PEG ratio of 0.66 and a beta of 1.49. Celgene Co. has a 1 year low of $88.32 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.09. The firm had revenue of $3.48 billion for the quarter, compared to analysts’ expectations of $3.46 billion. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The company’s revenue was up 16.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.61 EPS. analysts expect that Celgene Co. will post 7.68 earnings per share for the current year.

Celgene declared that its board has approved a share buyback plan on Wednesday, February 14th that authorizes the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to reacquire shares of its stock through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the stock a “hold” rating in a report on Tuesday, January 23rd. UBS Group lowered shares of Celgene from a “strong-buy” rating to a “market perform” rating and set a $160.00 target price for the company. in a report on Thursday, October 26th. BMO Capital Markets dropped their target price on shares of Celgene from $163.00 to $148.00 and set an “outperform” rating for the company in a report on Friday, October 27th. Barclays reaffirmed an “equal weight” rating and set a $105.00 target price (down previously from $135.00) on shares of Celgene in a report on Friday, October 27th. Finally, Deutsche Bank assumed coverage on shares of Celgene in a report on Tuesday, December 12th. They set a “hold” rating and a $114.00 target price for the company. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, eighteen have given a buy rating and two have given a strong buy rating to the company’s stock. Celgene currently has a consensus rating of “Buy” and an average target price of $130.25.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Capital Counsel LLC NY lifted its position in Celgene by 0.4% in the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after buying an additional 6 shares during the last quarter. Fort Pitt Capital Group LLC lifted its position in Celgene by 0.6% in the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after buying an additional 11 shares during the last quarter. TCI Wealth Advisors Inc. lifted its position in Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 26 shares during the last quarter. Linscomb & Williams Inc. lifted its position in Celgene by 1.0% in the second quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 36 shares during the last quarter. Finally, Courier Capital LLC lifted its position in Celgene by 1.9% in the second quarter. Courier Capital LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 38 shares during the last quarter. 77.84% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “Celgene Co. (CELG) Director Sells $887,907.50 in Stock” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/celgene-co-celg-director-sells-887907-50-in-stock.html.

About Celgene

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Insider Buying and Selling by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply